M&A Surge Predicted for Generics Industry

February 2011
Chain Drug Review;2/28/2011, Vol. 33 Issue 4, p58
Trade Publication
The article presents a study by Thomson Reuters Corp. called Gaining Market Share in the Generic Drug Industry Through Acquisitions and Partnerships which reveals that a wave of mergers & acquisitions (M&As) awaits the generic pharmaceutical industry buffeted by price cuts in the U.S.


Related Articles

  • Deal Making Heats Up in Global Arena.  // Chain Drug Review;7/16/2012, Vol. 34 Issue 12, p62 

    The article reports on the growing acquisition activity in the generic drug industry.

  • Going Off Patent: Standing Pat to Getting Out. O'Connell, Brian // BioPharm International;Jan2004, Vol. 17 Issue 1, p26 

    Focuses on the increase competition from generic drugs according to IMS Health Inc. and Reuters. Availability of prescription and generic drugs; Percentage of increase in sales of generic drugs in 2004; Priorities of government regulators regarding drug patents.

  • Industry Consolidation Raises Concern at HHS.  // Chain Drug Review;2/22/2016, Vol. 38 Issue 4, p69 

    The article discusses the U.S. Health and Human Services Department's (HHS) issue brief which noted that the mergers and acquisitions involving generic drug manufacturers may lead to fewer competitors producing a given generic.

  • Merck completes Japanese acquisition.  // Pharmaceutical Technology Asia;Apr2002, p6 

    Reports on the completion of the acquisition of generic drug company Mohan Medicine Research Institute of Tokyo, Japan by the Merck Generics Group. Purpose of the acquisition; Expectations of Merck from the acquisition; Information on generic drug sales in Japan, as of April 2002.

  • Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth.  // Biomedical Market Newsletter;11/9/2011, Vol. 21, p228 

    The article offers information on the report "Neurodegenerative Disease Market to 2017 - Patent Expiries of High Selling Drugs Such as Aricept, Namenda, Avonex, Rebif and Copaxone will Restrain Growth." It notes that the report provides in-depth analysis on the major neurodegenerative disease...

  • Report from: Brazil. Berger, Hellen // Pharmaceutical Technology;Mar2012, Vol. 36 Issue 3, p16 

    The article reports on the state of the generic-drug market in Brazil, which has improved due to lower prices compared to branded drugs. It mentions various generic products that had entered the country including atorvastatin, rosuvastatin and sildenafil, representing nearly 15% of the sector's...

  • Editorial. Rock, Stuart // Director;Feb1995, Vol. 48 Issue 7, p9 

    Editorial. Focuses on the rise of Reuters to superpower status in the world of information provision. Reason why Great Britain could be a leading nation in the information-driven 21st century; How Great Britain in rated in the world of technical telecommunications infrastructure; In which...

  • Today's news, tomorrow's company. Kay, Helen // Director;Feb1995, Vol. 48 Issue 7, p20 

    Profiles Reuters, the world's largest provider of electronic information. Establishment of the company; How the company has grown; Financial status of the company; Examination of the sales of financial information at the Great Britain-based company; Profile of the company's chief executive...

  • Reuters sees tech as ticket to ride. Whitestone, Randy // Inter@ctive Week;05/12/97, Vol. 4 Issue 15, p54 

    Reports on the growth of the global financial news and data company Reuters Holdings PLC. Total number of alliances with Web publishers; Acquisition of the two Internet companies Reality Online Inc. and Tibco Inc.; Total amount of revenue generated by the company.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics